



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/601,314	06/20/2003	Jian Zhao	056647-1017	6959
38706 75	590 07/29/2005		EXAM	INER
FOLEY & LARDNER LLP			DENTZ, BERNARD I	
1530 PAGE MILL ROAD PALO ALTO, CA 94304			ART UNIT	PAPER NUMBER
			1625	
			DATE MAILED: 07/29/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summary	10/601,314	ZHAO ET AL.				
	Examiner	Art Unit				
The MAILING DATE of this communication a	Bernard Dentz	1625				
Period for Reply	ppears on the cover sheet with the c	ion osponuoneo dadress				
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory perio - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the mai earned patent term adjustment. See 37 CFR 1.704(b).	I. 1.136(a). In no event, however, may a reply be tireply within the statutory minimum of thirty (30) day of will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 11 May 2005.						
2a)⊠ This action is FINAL. 2b)□ Th	This action is FINAL . 2b) This action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) ☐ Claim(s) 75-95 is/are pending in the applicat 4a) Of the above claim(s) is/are withdr 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 75-95 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and	rawn from consideration.					
Application Papers						
9)☐ The specification is objected to by the Exami	i e					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the corre	• •					
11)☐ The oath or declaration is objected to by the l		• • • • • • • • • • • • • • • • • • • •				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document of the priority document of the certified copies	nts have been received. nts have been received in Applicati ionty documents have been receive au (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 8) 5) Notice of Informal P 6) Other:					

Application/Control Number: 10/601,314

Art Unit: 1625

Applicants have replaced the elected claims with claims 75-95.

Claims 75-95 are rejected under 35 U.S.C. 102(b) as being anticipated by Vitasyn for basically the reasons of record.

Claims 75-95 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vitasyn for the reasons of record.

Claims 75-95 are rejected under 35 U.S.C. 102(b) as being anticipated by Abe et al for the reasons of record.

Claim 75-95 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abe et al for essentially the reasons of record.

Applicant's arguments filed 5-11-2005 have been fully considered but they are not per suasive. Note most importantly that Abe et al implicitly teaches that low density lipoprotein-cholesterol is lowered because it recites data showing that the theaflavins, the major component of black tea polyphenols, are excellent inhibitors of squalene epoxidase (SE). (SE) controls the throughput from squalene to sterols in cholesterol biogenesis. If sterols are reduced both high and low density lipoprotein-cholesterol would be reduced. Also note the next to last sentence at p.49, col. 1, par. 1. "Therefore, like green tea, black tea would be expected to be an excellent beverage for lowering cholesterol as well as cancer prevention."

Note in line with the above that both references relate that black and green teas can be used to treat hyperlipedemia. Note also the teaching of Vitasyn in the paragraph bridging p. 6 and 7 that epicatechin and epigallocatechin gallates of green tea were found to reduce LDL and the recitation of claim 16 that they and theaflavin and the

Application/Control Number: 10/601,314

Art Unit: 1625

theaflavin gallates improve the atherogenic index in persons with cardiovascular risk factors.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is 571-272-0683. The examiner can normally be reached on Mon-Fri from 8 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can be reached on 571 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

Application/Control Number: 10/601,314

Art Unit: 1625

Page 4

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Dentz

7-20-2005

BERNARD DENTZ PRIMARY EXAMINED CECUP 1200